Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.

Anthropic’s Claude agents outperformed human researchers and produced “alien science,” raising new questions about AI ...

在过去几年中，数据基础设施的演进始终围绕一个核心问题展开：如何更快地分析数据？ 但进入 2026 年，这个问题正在被重新定义。随着 AI 应用的爆发式增长，数据系统不再只是分析工具，而逐渐成为 智能系统的一部分。数据不再只是被查询，而是被 Agent ...

但进入 2026 年，这个问题正在被重新定义。随着 AI 应用的爆发式增长，数据系统不再只是分析工具，而逐渐成为 智能系统的一部分。数据不再只是被查询，而是被 Agent 调用、被模型理解、被系统实时消费。

包括GPT-OSS-20b（仅36亿激活参数）、DeepSeek R1在内的8款模型，全部成功检测出了这个复杂的栈缓冲区溢出漏洞。 最让人震撼的是，成功完成这项任务的开源小模型，其调用成本低至每百万Token 0.11美元。

AI界的「奥本海默时刻」竟是摆拍？Claude Mythos发现0day漏洞的能力过于「夸大了」，不仅有人工掺水，连开源GPT都能轻松踢馆。同时，Opus 4.6正经历最惨的「脑叶切除」。